Silk Road Medical Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Silk Road Medical Inc (SILK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Silk Road Medical Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 190M vs 291,058M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-30.0% annualized vs trailing 12 months), vs decelerating (-11.0%) for its tracked peer group.
- Growth: Silk Road Medical Inc generated 25.4% revenue growth year over year in Q2 2022, vs 3.3% for its competitors combined.
- Profitability: Its -46.4% net margin compares with 15.4% for the peer group.
- Peer revenue share: Silk Road Medical Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.40M compares with $0.45M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SILK Sales vs. its Competitors, Q2 2022
Silk Road Medical Inc reported revenue growth of 25.39 % year on year in Q2 2022, above its competitors' combined revenue growth of 3.31 %.
With a net margin of -46.42 %, Silk Road Medical Inc reported lower profitability than its competitors (15.40 %).
Silk Road Medical Inc generated 0.05 % of the combined sales of its peer group, up from 0.04 % a year earlier.
API endpoints for this dataset
Silk Road Medical Inc vs. its Competitors, Q2 2022
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Silk Road Medical Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Silk Road Medical Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Silk Road Medical Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Silk Road Medical Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 25.4% for Silk Road Medical Inc. Silk Road Medical Inc's share of combined industry revenue moved from 0.03% to 0.03%, a gain of 0.00 percentage points.
Silk Road Medical Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Silk Road Medical Inc | No | Yes | Yes | No |
| Competitors combined (44) | ||||
| High-Confidence Competitors (5) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SILK Stock Performance relative to its Competitors
SILK Stock Performance relative to High-Confidence Competitors
SILK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Vaso Corporation | 282.9% | Outperformed |
| 2 | Adagio Medical Holdings inc | 282.9% | Outperformed |
| 3 | Atricure Inc | 282.9% | Outperformed |
| 4 | Livanova Plc | 282.9% | Outperformed |
| 5 | Becton Dickinson And Company | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Silk Road Medical Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Silk Road Medical Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Silk Road Medical Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Silk Road Medical Inc |
1,089.18 | 189.67 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Abbott Laboratories |
192,651.69 | 46,585.00 |
 Medtronic Plc |
132,095.43 | 37,542.00 |
 Stryker Corp |
125,308.33 | 26,300.00 |
 Boston Scientific Corporation |
63,917.04 | 21,070.00 |
| SUBTOTAL | 1,435,685.98 | 291,267.88 |
Sign in to see all competitors of Silk Road Medical Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Silk Road Medical Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Silk Road Medical Inc's Competitors Named by the Company
Competitive relationships identified from Silk Road Medical Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inspiremd Inc | Company report | 85% |
| Contego Medical Inc. | Company report | 85% |
| Abbott | Company report | 85% |
| Cordis | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Boston Scientific | Company report | 85% |
| Medtronic | Company report | 85% |
| Cook Medical Inc. | Company report | 85% |
| Terumo | Company report | 85% |
| Cook | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Encision Inc | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Avinger Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Cardiovascular Systems Inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Abiomed Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Vaso Corporation | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Silk Road Medical Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Silk Road Medical Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.93 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Silk Road Medical Inc .
Silk Road Medical Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Silk Road Medical Inc | 1,089 | 400,143 | -119,278 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Abbott Laboratories | 192,652 | 405,087 | 47,174 |
| Medtronic Plc | 132,095 | 395,179 | 55,463 |
| Stryker Corp | 125,308 | 469,643 | 64,696 |
| Boston Scientific Corporation | 63,917 | 357,119 | 59,220 |
| PEERS TOTAL | 1,434,597 | 445,386 | 55,429 |
Sign in to see all peers for Silk Road Medical Inc .
Silk Road Medical Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 58.90 % |
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Silk Road Medical Inc .
Silk Road Medical Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 74.97 % | 46.20 % (avg) | +28.8 pp |
| Operating Margin | -31.73 % | industry median | -19.7 pp |
| EBITDA Margin | -26.48 % | -6.66 % (avg) | -19.8 pp |
| Capital Intensity (Capex / Revenue) | 1.12 % | 7.13 % (avg) | -6.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Silk Road Medical Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 36.9x | - |
| EV / EBITDA | - | 17.8x | - |
| P/B | 5.5x | 4.6x | +0.9x |
| Return on Equity | -37.30 % | industry aggregate | -44.62 % |
| Return on Invested Capital | -15.56 % | -6.78 % (avg) | -8.78 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Silk Road Medical Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue Growth | - | 34.89 % | 36.62 % | 27.73 % |
| Operating Margin | -44.30 % | -46.78 % | -37.51 % | -33.47 % |
| Return on Invested Capital | -23.23 % | -20.10 % | -21.06 % | -15.13 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Silk Road Medical Inc's Strategic Group Map
Silk Road Medical Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Silk Road Medical Inc's trailing-12-month revenue growth of 16.5% and operating margin of -31.7% compares with an average of 17.1% growth and -29.4% margin across its 8 closest peers by combined growth, margin and ROIC -- Silk Road Medical Inc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Silk Road Medical Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.12 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Silk Road Medical Inc's dedicated Suppliers and Customers pages, not here.
Silk Road Medical Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Silk Road Medical Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Silk Road Medical Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 19.7 points below the industry median.
- Return on equity 44.6 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-30.0% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-11.0% annualized).
Methodology: see Methodology: SWOT Analysis.
Silk Road Medical Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Silk Road Medical Inc | 0.88 | 8.94 | 0.50 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
Sign in to see all peers for Silk Road Medical Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Silk Road Medical Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Silk Road Medical Inc | Q2 2022 | +11.5 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| PEERS TOTAL | +7.6 % | -38.9 % |
Sign in to see all peers for Silk Road Medical Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Silk Road Medical Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Silk Road Medical Inc | Q2 2022 | -7.7 % | +119.8 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
Sign in to see all peers for Silk Road Medical Inc .
Silk Road Medical Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Silk Road Medical Inc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
Sign in to see all peers for Silk Road Medical Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Silk Road Medical Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Silk Road Medical Inc | - | 5.74 |
| Johnson and Johnson | 42.68 | 6.95 |
| Abbott Laboratories | 35.54 | 4.14 |
| Medtronic Plc | 302.32 | 3.52 |
| Stryker Corp | 34.69 | 4.76 |
| Boston Scientific Corporation | 18.68 | 3.03 |
| PEERS AVERAGE | 39.69 | 4.93 |
Sign in to see all peers for Silk Road Medical Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.